Get the Stockscreener App
6.01
0.00%
0.00
After Hours:
5.96
-0.05
-0.83%
Mannkind Corp stock is traded at $6.01, with a volume of 3.39M.
It is up +0.00% in the last 24 hours and up +1.35% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$6.01
Open:
$6.04
24h Volume:
3.39M
Relative Volume:
1.28
Market Cap:
$1.66B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
120.20
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-1.31%
1M Performance:
+1.35%
6M Performance:
+3.62%
1Y Performance:
+83.23%
1-Day Range:
$5.785
$6.04
1-Week Range:
$5.785
$6.32
52-Week Range:
$3.17
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
6.01 | 1.66B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind (NASDAQ:MNKD) Shares Down 3.1%Should You Sell? - MarketBeat
MannKind Co. (NASDAQ:MNKD) Sees Large Drop in Short Interest - MarketBeat
MannKind appoints new EVP as executive plans retirement - Investing.com
MannKind Expands Executive Leadership Team - Yahoo Finance
Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
MNKDMannkind Corporation Latest Stock News & Market Updates - StockTitan
MannKind expecting to ‘practically double in size’ with new hires in Danbury - Westfair Online
MannKind Co. (NASDAQ:MNKD) Receives $8.88 Average PT from Analysts - MarketBeat
MannKind Co. (NASDAQ:MNKD) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Geode Capital Management LLC Has $39.88 Million Stock Holdings in MannKind Co. (NASDAQ:MNKD) - Defense World
MannKind Target of Unusually High Options Trading (NASDAQ:MNKD) - Defense World
MannKind (NASDAQ:MNKD) Stock Price Down 3.1%What's Next? - MarketBeat
Barclays PLC Buys 338,121 Shares of MannKind Co. (NASDAQ:MNKD) - Defense World
Barclays PLC Purchases 338,121 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
Exploring 3 High Growth Tech Stocks In The United States - Yahoo Finance
MannKind (NASDAQ:MNKD) Research Coverage Started at Wells Fargo & Company - Defense World
FY2025 EPS Estimates for MannKind Lowered by Leerink Partnrs - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for MannKind - Defense World
Wells Fargo Initiates Coverage of MannKind (MNKD) with Overweight Recommendation - MSN
MannKind stock up 10% amid bullish Wells Fargo note - MSN
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wells Fargo & Company - MarketBeat
MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years - Yahoo Finance
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
RBC Capital Upgrades MannKind (MNKD) - MSN
MannKind (NASDAQ:MNKD) Trading Up 5.7%Here's Why - MarketBeat
3 High-Growth Biotech Stocks to Watch - Inkl
MannKind (NASDAQ:MNKD) Upgraded to Outperform at Royal Bank of Canada - MarketBeat
Tyvaso DPI royalties and pipeline potential boost MannKind stock—RBC - Investing.com
Noteworthy Wednesday Option Activity: MNKD, BTU, FSLR - Nasdaq
MannKind (NASDAQ:MNKD) Shares Gap UpShould You Buy? - MarketBeat
MannKind to issue shares in debt exchange deal - Investing.com
MannKind to issue shares in debt exchange deal By Investing.com - Investing.com Canada
MannKind trims debt with $194 million note exchange By Investing.com - Investing.com Canada
MannKind to reduce debt by 84% - MSN
MannKind trims debt with $194 million note exchange - Investing.com
MannKind Slashes Debt by 84% in Major Financial Restructuring, Converts $194M Notes to Equity - StockTitan
HighTower Advisors LLC Buys 107,560 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind (NASDAQ:MNKD) Stock Price Down 5.4%Here's Why - MarketBeat
MannKind Becomes Oversold (MNKD) - Nasdaq
Wellington Management Group LLP Acquires 85,977 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) - Barchart
Mannkind Corp (MNKD-Q) QuotePress Release - The Globe and Mail
MannKind Announces Six-Month Results From Phase 3 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Stake in MannKind Co. (NASDAQ:MNKD) - Defense World
Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience’ for those with diabetes - BusinessLine
CDSCO approves Cipla to distribute, market inhaled insulin in India - Daijiworld.com
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - Yahoo Finance
Cipla gets CDSCO nod to launch inhalation insulin - The Economic Times
Two Sigma Advisers LP Buys 1,000,600 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
MannKind (NASDAQ:MNKD) Cut to "Hold" at StockNews.com - MarketBeat
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):